


ASENT 2021 ANNUAL MEETING

February 22-25, 2021

**Virtual Neuroscience and
Neurotherapeutics Conference**



ADVANCE PROGRAM



A Quick Look at ASENT 2021

Annual Meeting Overview

ASENT 2021 is the premier neurotherapeutics conference where senior leaders from leading payers, providers, employers, investors, fast-growing startups, pharma, policymakers, funders and innovation centers in the neurology and neuroscience space gather to ask one question: how can we improve the process of bringing neurotherapeutics to market?

The conference content will focus on the latest science in neurotherapeutics including innovations across disease states, novel delivery systems, gene therapy and biomarkers, and of course the latest drug therapies and devices. The event features plenary sessions, panel discussions, networking meetings, outstanding pipeline presentations and poster sessions.

MEETING DETAILS

ASENT 2021 Meeting Dates

Monday, February 22 -

Thursday, February 25, 2021

VIRTUAL FORMAT

Abstract Submissions

Open through December 21, 2020

<https://www.eventbrite.com/e/126563507859>

REGISTRATION IS OPEN

Annual Meeting Registration Deadline

February 15, 2021

<https://www.eventbrite.com/e/125915487613>

Meeting Location

ONLINE

WHO ATTENDS

Clinician-investigators

Neuroscientists

Industry research scientists

Clinical and Experimental

Neuroscience Trainees

Advocacy Group Leaders

Chief Medical Officers

CEOs

Founders

Funders

Investors

Innovation Centers

Journal Editors

Drug and Device Companies

Communication Companies

Health Systems

Chairs of Neurology

Executive Directors

FDA

NINDS

NIMH

NIA

ALL ARE WELCOME!

WHAT IS ASENT?


The **American Society for Experimental Neurotherapeutics (ASENT)** is an independent non-profit organization established in 1997 by leaders in academia, government, advocacy and industry to facilitate the process by which new therapies are made available to patients with neurological disorders. Its primary goal is to encourage and advance the development of improved therapies for diseases and disorders of the nervous system.

Register for ASENT 2021

Online Registration

In light of these unique times, the American Society for Experimental Neurotherapeutics has decided to make the 2021 Annual Meeting free to all attendees. Don't miss this opportunity to access outstanding content, poster sessions and pipeline presentations.

FREE TO REGISTERED ATTENDEES



Register Today:
www.eventbrite.com/e/125915487613

ASENT 2021 SCHEDULE AT A GLANCE

MONDAY			
10:00am - 11:35am	Symposium	COVID-19 and the nervous system as a basic medical and therapeutic challenge	
11:35am - 11:45am	BREAK		
11:45am - 1:00pm	Concurrent Symposia	Obstacles and Opportunities in Alzheimer's Disease Neurotherapeutics	RNA editing and CRISPR technology: basic approaches and treatment implications for neurologic disease
1:00pm - 1:15pm	Comments from President		
1:15pm - 1:30pm	BREAK		
1:30pm - 2:00pm	Sponsored Symposium		
2:00pm - 3:00pm	Poster Presentations		
TUESDAY			
10:00am - 11:15am	Concurrent Symposia	New and Emerging Therapeutics for Epilepsy	Dystonia: Genetics, pathophysiology, new targets and treatment
11:15am - 11:30am	BREAK		
11:30am - 12:45pm	Pipeline	PIPELINE PRESENTATIONS: Emerging Neurotherapeutics Pipeline	
12:45pm - 1:00pm	Comments from President		
1:00pm - 2:00pm	Sponsored Symposium		
2:00pm - 3:00pm	Poster Presentations		

ASENT 2021 SCHEDULE AT A GLANCE

WEDNESDAY			
10:00am - 11:15am	Concurrent Symposia	Epigenetics in Neurodegenerative Disorders	Emerging therapeutics in NeuroOncology
11:15am - 11:30am	BREAK		
11:30am - 12:45pm	Pipeline	PIPELINE PRESENTATIONS: Emerging Neurotherapeutics Pipeline	
12:45pm - 1:00pm	Comments from President		
1:00pm - 2:00pm	Sponsored Symposium		
2:00pm - 3:00pm	Poster Presentations		
THURSDAY			
10:00am - 11:15am	Concurrent Symposia	Brain Organoids as Models of Neurological Disorders and Treatment	Parkinson's Disease: New Approaches
11:15am - 11:30am	BREAK		
11:30am - 12:45pm	Pipeline	PIPELINE PRESENTATIONS: Emerging Neurotherapeutics Pipeline	
12:45pm - 1:00pm	Meeting Conclusion and Comments from President		
1:00pm - 2:00pm	Sponsored Symposium		
2:00pm - 3:00pm	Poster Presentations		

DAY 1 | MONDAY, FEBRUARY 22, 2021

10:00am - 11:35am	PRESIDENTIAL SYMPOSIUM: COVID-19 and the nervous system as a basis medical and therapeutic challenge	
	Chairs: Thomas Sutula, MD, PhD, University of Wisconsin C. Anthony Altar, PhD, Splice Therapeutics Carole Burns, PhD	
	Symposium to cover 1918 flu pandemic, the 2020 COVID-19 pandemic and neurological consequences. Stroke, olfactory (anosmia) and gustatory deficits and other neurological complications result from COVID-19 infection. The delayed appearance of postencephalitic Parkinsonism in people surviving the 1918 flu and those contracting encephalitis lethargica around the same time indicate hidden, protracted risks may await those who survive viral pandemics. These topics and an update of neurological complications of COVID-19 will be reviewed in this symposium.	
	FACULTY	
10:00am - 10:30am	KEYNOTE PRESENTATION: Neurological Consequences of Viral Pandemics including COVID-19 <i>Avindra Nath, MD, National Institute of Neurological Disorders and Stroke</i>	
10:30am - 10:40am	Live Q&A with KEYNOTE SPEAKER	
10:40am - 10:45am	BREAK	
10:45am - 11:05am	<i>Serena S. Spudich, MD, Neuroinfectious Diseases and Global Neurology, Yale University School of Medicine</i>	
11:05am - 11:25am	<i>Arvid Edén, MD, Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg</i>	
11:25am - 11:35am	Live Faculty Panel Discussion and Q&A	
11:35am - 11:45am	BREAK	
11:45pm - 1:00pm	Obstacles and Opportunities in Alzheimer's Disease Neurotherapeutics	RNA editing and CRISPR technology: basic approaches and treatment implications for neurologic disease
	Chairs: Bennett Lavenstein, MD, Children's National Sharon Tamir, Karyopharm	Chairs: Ann-Marie Broome, MBA, PhD, NINDS Lloyd Mitchell, MD, RetroTherapy
	Speakers will address barriers to success, the use of natural history and investigation of drug repurposing in the search for solutions in Alzheimer's Disease neurotherapeutics.	Discussion of gene editing as an advancement in gene therapy including DNA and RNA editing, Molecular mechanisms, clinical potentials of genome editing systems, and therapeutic development in neurological disorders.
	FACULTY	FACULTY
11:45am - 12:05pm	Advances in Alzheimer's Disease and Related Dementia Research <i>Eliezer Masliah, MD, National Institute on Aging</i>	Base Editing and Prime Editing: Genome Editing Without Double-Strand Breaks <i>David R. Liu, PhD, Merkin Institute of Transformative Technologies in Healthcare, Broad Institute, Harvard University, Howard Hughes Medical Institute</i>
12:05pm - 12:25pm	Leveraging Dominantly Inherited Alzheimer Disease for Current and Future Alzheimer Therapeutics <i>Eric McDade, DO, Washington University School of Medicine in St. Louis</i>	SESSION TITLE TBD Lloyd Mitchell, MD, RetroTherapy
12:25pm - 12:45pm	Barriers to success /opportunities in Alzheimer's on the basis of prior or forthcoming trials <i>Dennis Selkoe, MD, Harvard Medical School and Brigham and Women's Hospital</i>	Invited Speaker
12:45pm - 1:00pm	Live Faculty Panel Discussion and Q&A	
1:00pm - 1:15pm	Closing comments from ASENT President	

DAY 2 | TUESDAY, FEBRUARY 23, 2021

10:00am - 11:15am	Leveraging Unconventional (Big) Clinical Datasets for Treatment in Epilepsy	Dystonia: Genetics, pathophysiology, new targets and treatment
	Chairs: Aditya Joshi, MD, University of Pennsylvania Danilo Vitorovic, MD, University of Vermont Gail Farfel, PhD, Zogenix	Chairs: Stewart Factor, MD, Emory University Debra Ehrlich, MD, NINDS
	There is vast amount of data generated in the modern clinical practice of epilepsy, which is now more accessible than ever with the tools of Big Data. In this symposium, we will explore some of the efforts to tap this vast trove to advance the treatment of patients with epilepsy.	Faculty will address genes and mechanisms in Dystonia, pathophysiology specific to dystonia as well as, new targets and treatments to address the disease state.
	FACULTY	FACULTY
10:00am - 10:20am	Natural Language Processing of EEG Reports to Learn Seizure Onsets <i>Christopher Lee-Messer, MD, PhD, Stanford University</i>	Dystonia Genes & Mechanisms <i>Hyder A. (Buz) Jinnah, MD, Emory School of Medicine</i>
10:20am - 11:40am	Discovering Genotype-Phenotype Correlations Hidden in the EMR <i>Colin Ellis, MD, Children's Hospital of Philadelphia</i>	Pathophysiology in Dystonia <i>Mark Hallett, MD, National Institute of Neurological Disorders and Stroke</i>
10:40am - 11:00am	Applying artificial intelligence to epilepsy care: from scanner to bedside <i>Ezequiel Gleichgerrcht, MD, PhD, Medical University of South Carolina</i>	New Targets and Treatments in Dystonia <i>Susan Fox, MB ChB, MRCP, PhD, University of Toronto</i>
11:00am - 11:15am	Live Faculty Panel Discussion and Q&A	Live Faculty Panel Discussion and Q&A
11:15am - 11:30am	BREAK	
	PIPELINE PRESENTATIONS: Emerging Neurotherapeutics Pipeline	
11:30am - 12:30pm	6 presentations each day/10 minutes each	
12:30pm - 12:45am	Live Faculty Panel Discussion and Q&A	
12:45pm - 1:00pm	Closing comments from ASENT President	

DAY 3 | WEDNESDAY, FEBRUARY 24, 2021

10:00am - 11:15am	Physiological markers and epigenetic risk factors in neurodegenerative disorders	Emerging therapeutics in NeuroOncology
	Chairs: Amy Chappell, MD, Eliem Suhayl Dhib-Jalbut, MD, UMDNJ-Rutgers	Chairs: Sharon Tamir, Karyopharm
	This session will cover the physiological markers of stress and aging, epigenetic regulation of myelination and demyelination, and MS susceptibility variants exert local and distal effects on the T cell epigenome.	Glioblastoma Multiforme (GBM) is one of the most common and particularly aggressive forms of brain tumors of primarily glial cell origin. GBM is an incurable disease with few treatment advances for many years. Speakers will discuss new potential treatments and development in the field of GBM and other neuro-oncology diseases
	FACULTY	FACULTY
10:00am - 10:20am	Multiple sclerosis susceptibility variants exert local and distal effects on the T cell epigenome <i>Philip deJager, MD, PhD, Columbia University</i>	New horizons for TTFIELDS in neuro-oncology <i>Moshe Giladi, PhD, MBA, Novocure, Ltd.</i>
10:20am - 11:40am	Physiological markers of stress and aging <i>David Ziegler, PhD, University of California, San Francisco</i>	Selinexor, Selective Inhibitor of Nuclear Export (SINE) compound in neuro-oncology <i>Paul Duic, MD, Karyopharm</i>
10:40am - 11:00am	Epigenetic regulation of myelination and remyelination <i>Patrizia Casaccia, MD, PhD, Icahn School of Medicine</i>	Using the Mayo GBM PDX collection as a platform for developing novel combination therapies for GBM <i>Jann Sarkaria, MD, Mayo Clinic</i>
11:00am - 11:15am	Live Faculty Panel Discussion and Q&A	Live Faculty Panel Discussion and Q&A
11:15am - 11:30am	BREAK	
	PIPELINE PRESENTATIONS: Emerging Neurotherapeutics Pipeline	
11:30am - 12:30pm	6 presentations each day/10 minutes each	
12:30pm - 12:45pm	Live Faculty Panel Discussion and Q&A	
12:45pm - 1:00pm	Closing comments from ASENT President	

DAY 4 | THURSDAY, FEBRUARY 25, 2021

10:00am - 11:15am	Brain Organoids as Models of Neurological Disorders and Treatment	Parkinson's Disease: New Approaches
	Chairs: C. Anthony Altar, Splice Therapeutics Amir Tamiz, PhD, NINDS	Chairs: Stewart Factor, MD, Emory University Debra Ehrlich, MD, NINDS
	Speakers will describe the technology behind creating three-dimensional cell clusters that resemble peripheral and central nervous tissue, and how these CNS and PNS models show phenotypes consistent with CNS tissue, and diseases that plagued donors of the progenitor cells used to make these cell systems. The use of organoids to evaluate known and novel therapeutic agents, including gene therapies, will also be shown.	Speakers will discuss Stem cells, C-ABL therapy, and exercise in the context of Parkinson's Disease therapeutic gaps and developments.
	FACULTY	FACULTY
10:00am - 10:20am	Modelling physiology and disease with brain organoids <i>Thomas Hartung, MD, Johns Hopkins University</i>	Stem cells therapy in Parkinson's Disease <i>Howard Federoff, MD, PhD, Aspen Neuroscience</i>
10:20am - 11:40am	Optimization and scaling of patient-derived brain organoids for disease phenotyping and drug discovery <i>Gaia Skibinski, PhD, System1 Biosciences</i>	Disease modification of Parkinson's Disease through oral kinase inhibitor therapy <i>Milton Werner, PhD, Inhibikase Therapeutics</i>
10:40am - 11:00am	3D Neuronal Spheroids and Organoids for Disease Modeling and Drug Discovery <i>Emily Lee, PhD, National Institute on Aging</i>	Therapeutically Beneficial Effects of Exercise on Parkinson's Disease <i>Daniel Corcos, PhD, Northwestern Medicine</i>
11:00am - 11:15am	Live Faculty Panel Discussion and Q&A	Live Faculty Panel Discussion and Q&A
11:15am - 11:30am	BREAK	
	PIPELINE PRESENTATIONS: Emerging Neurotherapeutics Pipeline	
11:30am - 12:30pm	6 presentations each day/10 minutes each	
12:30pm - 12:45am	Live Faculty Panel Discussion and Q&A	
12:45pm - 1:00pm	Meeting Conclusion and Closing comments from ASENT President	

ASENT Leadership

PROGRAM COMMITTEE

CHAIRS

C Anthony Altar, PhD, Chair
Splice Therapeutics
Sharon Tamir, Co-Chair
Karyopharm

COMMITTEE MEMBERS

Carole Burns, PhD
Enrique Carrazana, MD
Marinus Pharmaceuticals
Amy Chappell, MD
Eliam
Suhayl Dhib-Jalbut, MD
Rutgers-Robert Wood Johnson Medical School
Tracy Dixon-Salazar, PhD
Lennox Gastaut Foundation
Debra Ehrlich, MD, MS
NINDS
Stewart Factor, DO
Emory University
Gail Farfel, PhD
Zogenix
Wendy Galpern, MD, PhD
Johnson and Johnson
Dietrich Haubenberger, MHSc, MD
Neurocrine
Aditya Joshi, MD
University of Pennsylvania
Laura Rosen, MD, PhD
Takeda
Cynthia Rothblum-Oviatt, PhD
RO Scientific
Nancy Santilli, MSN
Human Care Systems
Steve Schachter, MD
CIMIT/Harvard Medical School
Carolyn Tallon, PhD
Johns Hopkins University
Danilo Vitorovic, MD
University of Vermont

EX-OFFICIO PROGRAM COMMITTEE MEMBERS

Thomas Sutula, MD, PhD
University of Wisconsin, Madison
Martha Morrell, MD, PhD
NeuroPace, Inc.
Bennett Lavenstein, MD
Children's National Health System
Amir Tamiz, PhD
NINDS
Robert Hamill, MD
University of Vermont
Barbara Slusher, MAS, PhD
Johns Hopkins University
Michael Rogawski, MD, PhD
University of California, Davis

BOARD OF DIRECTORS

EXECUTIVE COMMITTEE

Thomas Sutula, MD, PhD, PRESIDENT
University of Wisconsin
O'Neill D'Cruz, MD, MBA, FAAN, TREASURER
OD Consulting and Neurological Services, PLLC
Martha Morrell, MD, PAST PRESIDENT
NeuroPace

COMMITTEE MEMBERS

Enrique Carrazana, MD
Marinus Pharmaceuticals
Amy Chappell, MD
Eliam
Stewart A. Factor, DO
Emory University School of Medicine
Gail Farfel, PhD
Zogenix
Toby Ferguson, MD, PhD
Biogen Idec, Inc
Dietrich Haubenberger, MHSc, MD
Neurocrine
Aditya Joshi, MD
University of Pennsylvania
Bennett L. Lavenstein, MD
Children's Hospital Medical Center
Steven Schachter, MD
CIMIT/Harvard Medical School

David Shoup
Curry Rockefeller Group
Kenneth Sommerville, MD
Sommerville Consulting
Sharon Tamir
Karyopharm
Danilo Vitorovic, MD
University of Vermont

EX-OFFICIO BOARD

Amir Tamiz, PhD
NINDS
Michael Rogawski, MD, PhD
University of California, Davis
M. Maral Mouradian, MD
Rutgers University



Register Today:
www.eventbrite.com/e/125915487613